The efficacy of treating malignant glioblastoma multiforme (GB) with adjuvant therapies remains largely unsuccessful due to the inability to effectively target invading cells. Fn14 expression level is elevated in advanced glial tumors. Fn14-induced glioma invasion is mediated by the small GTPase Rac1;deletion of the TRAF binding region of Fn14 failed to activate Rac1 protein. We found that Ect2, a guanine nucleotide exchange factor (GEF), is overexpressed in GBM, and that overexpression of both Ect2 and Fn14 is correlated directly with tumor grade and inversely with patient outcome. Ect2 can associate with the Fn14 cytoplasmic complex and regulate Rac1 activation. Rac1 is a ubiquitous in many normal tissues, however the central position of Rac1 as a downstream player in many signaling pathologies operating in malignant states, suggest that targeting key regulators of Rac1 should be exploited to discover key vulnerabilities for invading glioma cells. We HYPOTHESIZE that Fn14 operates via Rac1 to enhance malignant glioblastoma cell invasion and survival.
The specific aims are as follow: 1) to define the proximal mechanism(s) by which the Fn14 activates Rac1 in glioma cells. We will query a specific biochemical model of the signaling protein(s) involved in Fn14- mediated Rac1 activation. We will first validate the role of Ect2 in this Fn14 induced Rac1 activation and determine whether Ect2 is a direct exchange factor for Rac1 or indirect exchange factor for Rac1 via Cdc42 activation downstream of Fn14. Secondly, we will determine whether Ect2 binds directly or indirectly to the TRAF site of the Fn14's cytoplasmic tail. 2) to demonstrate the impact of the Fn14-Rac1 signaling axis on glioma migration, invasion and therapy response. Biological validation using siRNAs directed to suppress the expression levels of the Fn14 signaling proteins (Ect2, TRAFs) will be performed to assess the effects of these proteins on glioma cell migration in vitro, cell invasion using ex vivo rat brain slices, and vulnerability of invasive glioma cells to cytotoxic therapy in vitro. Additionally, validation of the abundance and activation of Fn14 signaling proteins will be determined using immunohistochemical (IHC) techniques on glioma invasion TMAs. 3) to determine whether inhibition of Fn14 or its signaling protein(s) in glioblastoma xenografts leads to reduced tumor growth and cell invasion and facilitated activation of cell death in vivo. Inhibition and manipulation of Fn14 signaling components using blocking monoclonal antibodies to human Fn14 or shRNA directed against Fn14 signaling protein(s) (Ect2) will be used to assess the suitability of Fn14 and its signaling components as targeted therapies for invasive primary human malignant glioblastoma xenografts. Orthotopic models of GBMs will be used to assess effects of these biological therapies on induction of cell death by the cytotoxic agent temozolomide (Temador). Median cohort survival (Kaplan-Meier) as well as histological assessment of tumor size, invasion pattern and cell death in addition to examination of downstream signaling targets (Rac1 and NF:B activation) by ELISA and IHC techniques will be employed to measure the effectiveness of the biological therapies. PROJECT NARRATIVE: A hallmark of glioblastoma multiforme (GBM) is the ability of tumor cells to invade into surrounding normal brain. These invading cells are missed by surgery, escape focused radiation, and hide from chemotherapy. Preliminary studies demonstrate that the transmembrane receptor, Fn14, is upregulated with glioma progression;Fn14 expression correlates inversely with poor patient outcome. The activation of Fn14 mediates cell invasion and survival phenotypes of these malignant cells. Thus, the use of therapy against the transmembrane receptor Fn14 or its signaling proteins as an adjuvant to surgical extirpation may specifically target invasive glioma cells and improve the outcome of this devastating cancer. PROJECT NARRATIVE A hallmark of glioblastoma multiforme (GBM) is the ability of tumor cells to invade into surrounding normal brain. These invading cells are missed by surgery, escape focused radiation, and hide from chemotherapy. Preliminary studies demonstrate that the transmembrane receptor, Fn14, is upregulated with glioma progression;Fn14 expression correlates inversely with poor patient outcome. The activation of Fn14 mediates cell invasion and survival phenotypes of these malignant cells. Thus, the use of therapy against the transmembrane receptor Fn14 or its signaling proteins as an adjuvant to surgical extirpation may specifically target invasive glioma cells and improve the outcome of this devastating cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA130940-05
Application #
8260789
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Ault, Grace S
Project Start
2008-07-01
Project End
2013-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
5
Fiscal Year
2012
Total Cost
$336,935
Indirect Cost
$155,787
Name
Translational Genomics Research Institute
Department
Type
DUNS #
118069611
City
Phoenix
State
AZ
Country
United States
Zip Code
85004
Cheng, Emily; Whitsett, Timothy G; Tran, Nhan L et al. (2015) The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion. Mol Cancer Res 13:575-83
Murray, D W; Didier, S; Chan, A et al. (2014) Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation. Br J Cancer 110:1307-15
Whitsett, Timothy G; Mathews, Ian T; Cardone, Michael H et al. (2014) Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response. Mol Cancer Res 12:550-9
Dhruv, Harshil D; Whitsett, Timothy G; Jameson, Nathan M et al. (2014) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation. Carcinogenesis 35:218-26
Whitsett, Timothy G; Fortin Ensign, Shannon P; Dhruv, Harshil D et al. (2014) FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion. Clin Exp Metastasis 31:613-23
Salhia, Bodour; Kiefer, Jeff; Ross, Julianna T D et al. (2014) Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One 9:e85448
Asrani, Kaushal; Keri, Ruth A; Galisteo, Rebeca et al. (2013) The HER2- and heregulin ?1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Mol Cancer Res 11:393-404
Dhruv, Harshil D; McDonough Winslow, Wendy S; Armstrong, Brock et al. (2013) Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells. PLoS One 8:e72134
Kim, Tai Young; Jackson, Sarah; Xiong, Yue et al. (2013) CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci U S A 110:16868-73
Porter, Holly A; Perry, Anthony; Kingsley, Chris et al. (2013) IRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumors. Cancer Lett 338:239-48

Showing the most recent 10 out of 17 publications